Literature DB >> 23402689

Effects of the side of arteriovenous fistula on outcomes after coronary artery bypass surgery in hemodialysis-dependent patients.

Yoshiyuki Takami1, Kazuyoshi Tajima2, Wataru Kato2, Kei Fujii2, Makoto Hibino2, Hisaaki Munakata2, Yoshimasa Sakai2.   

Abstract

OBJECTIVE: The aim of the study was to determine whether using the in situ internal thoracic artery (ITA) graft ipsilateral to the arteriovenous fistula adversely affects the outcomes after isolated coronary artery bypass grafting (CABG) in the dialysis-dependent patients to answer the concerns of a possible steal and consequent myocardial ischemia.
METHODS: We categorized 155 dialysis patients undergoing isolated CABG between January 1993 and December 2011 into 108 patients (70%, ipsilateral group) whose left anterior descending artery (LAD) was revascularized with the ITA ipsilateral to the arteriovenous fistula and 47 patients (contralateral group) whose LAD was grafted with the ITA opposite to the fistula, to compare their early and late outcomes.
RESULTS: While 94% of the ipsilateral group had left fistula, 55% of the contralateral group had left fistulas. The LAD was grafted with the left ITA in 94% of the ipsilateral group, whereas it was grafted with left (49%) or right (51%) ITAs in the contralateral group. There was no significant difference in hospital mortality between the groups (ipsilateral 10.2% vs contralateral 10.6%). After follow-up for 55 ± 42 months, the overall survival (ipsilateral 58% vs contralateral 65% at 5 years) and cardiac event-free rates (ipsilateral 74% vs contralateral 68% at 5 years) were also similar between the groups by log-rank tests (P = .90 and P = .07).
CONCLUSIONS: Revascularization of the LAD using the in situ ITA graft ipsilateral to the arteriovenous fistula increases neither the operative mortality nor the risks of late death and cardiac events after isolated CABG in dialysis patients.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  23.1.1; AV; CABG; CI; CPB; DM; HD; HR; ITA; LAD; LVEF; MACE; arteriovenous; cardiopulmonary bypass; confidence interval; coronary artery bypass grafting; diabetes mellitus; hazard ratio; hemodialysis; internal thoracic artery; left anterior descending coronary artery; left ventricular ejection fraction; major adverse cardiac events

Mesh:

Year:  2013        PMID: 23402689     DOI: 10.1016/j.jtcvs.2013.01.031

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Effects of upper-extremity vascular access creation on cardiac events in patients undergoing coronary artery bypass grafting.

Authors:  Youngjin Han; Suk Jung Choo; Hyunwook Kwon; Jae Won Lee; Cheol Hyun Chung; Hyangkyoung Kim; Tae-Won Kwon; Yong-Pil Cho
Journal:  PLoS One       Date:  2017-09-05       Impact factor: 3.240

2.  Long-term prognosis in patients with end-stage renal disease after coronary artery bypass grafting.

Authors:  Philip Y K Pang; Christopher K J Teow; Ming Jie Huang; Madhava J Naik; See Lim Lim; Victor T T Chao; Teing Ee Tan; Yeow Leng Chua; Yoong Kong Sin
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

3.  Influence of Ipsilateral Graft Inflow to Arteriovenous Fistula for Hemodialysis in Coronary Bypass Surgery.

Authors:  Bongyeon Sohn; Hyoung-Woo Chang; Jae-Hang Lee; Dongjung Kim; Junsung Kim; Cheong Lim; Kay-Hyun Park
Journal:  J Clin Med       Date:  2022-02-17       Impact factor: 4.241

4.  Long-Term Outcomes in Coronary Artery Bypass Graft Patients Using Internal Thoracic Artery with Ipsilateral Arteriovenous Shunt for Hemodialysis.

Authors:  Yung-Szu Wu; Shih-Rong Hsieh; Hao-Ji Wei; Chiann-Yi Hsu; Chung-Lin Tsai
Journal:  Acta Cardiol Sin       Date:  2019-07       Impact factor: 2.672

5.  Internal thoracic artery graft ipsilateral to the arteriovenous fistula in haemodialysis patients.

Authors:  Kohei Hachiro; Takeshi Kinoshita; Tomoaki Suzuki; Tohru Asai
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.